Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 13.6
Key Takeaways
Risk factor
Strong trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Strong margins and returns
Data is available to registered users only
Data is available to registered users only
About
Shenzhen YHLO Biotech Co., Ltd. engages in developing, manufacturing, and distributing in-vitro diagnostic instruments and reagents in China. It offers clinical solutions for autoimmune, reproductive health, infectious, and other diseases; CLIA test panels, chemiluminescence immunoassay analyzers, and integration systems for immunoassay; ELISA test panels and immune analyzers; LIA test panels, blot analyzers, and line immunoassays;...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA
Data is available to registered users only
Buy
Sell